Health
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complicationsA study of people with obesity (STEP UP trial) showed that more people taking Wegovy® achieved a BMI under 27 and a waist-to-height ratio of less than 0.53, com
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss only","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Body mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complications","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"A study of people with obesity (STEP UP trial) showed that more people taking Wegovy® achieved a BMI under 27 and a waist-to-height ratio of less than 0.53, compared to none of the people taking the placebo1","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Most people treated with Wegovy® who achieved both these targets had their blood pressure, cholesterol and blood sugar levels return to healthy levels associated with low risk of cardiovascular disease1","length":202,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":749,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 5 November 2025 – Today, at ObesityWeek® taking place on 4-7 November in Atlanta, US, Novo Nordisk presented new findings from the STEP UP phase 3b trial. It showed that, in addition to losing an average of 21% of their body weight, Wegovy® (the approved semaglutide 2.4 mg dose and investigational higher 7.2 mg dose) enables people with obesity to achieve treatment targets associated with a low risk of obesity-related complications.1,2","length":458,"tagName":"p"},{"type":"text","content":"Unlike many other diseases, there are no established guidelines on which treatment targets doctors should use for treating obesity, with outcomes often relying only on percentage weight loss. A primary consideration in the managem...